President Trump’s executive order on pharmaceutical pricing is a wake-up call. For pharma companies, the question is not whether or not to react—but how. And how pharma companies react will have a big impact on where this debate ends. Reframe the narrative right and they have a unique opportunity to shift the conversation and become champions of both innovation and accessibility. Here’s thoughtful guidance for a constructive response.

Continue reading →